Biote Swings to Q2 Loss, Slashes Full-Year Outlook as Recall Fallout Persists
BTMD sits 55% above its 52-week low of $1.27 on light trading volume (0.3× avg).
Summary
Biote posted a Q2 net loss of $7.4M on revenue of $44.2M, down 9.5% year-over-year, and slashed its full-year outlook as the voluntary product recall continues to hurt procedure revenue and margins.
Updates
· SEC 10-Q — The 10-Q discloses a $175.0M amended credit agreement with Truist Bank on May 8, 2026, comprising a $50.0M revolving facility and a $125.0M term loan, with interest at SOFR plus 2.5% or 2.75%.
Key Events · Earnings and Guidance · BTMD
-
Q2 Revenue Falls 9.5%
Total revenue of $44.2M, down from $48.9M in Q2 2025, driven by a 13.9% decline in procedure revenue to $30.3M due to the ongoing voluntary pellet recall.
-
Swings to Net Loss
Net loss of $(7.4)M, or $(0.23) per share, compared to net income of $3.9M, or $0.10 per share, in the prior-year quarter. Operating loss was $(3.5)M versus income of $10.8M.
-
Adjusted EBITDA Plunges
Adjusted EBITDA fell to $5.6M (12.6% margin) from $15.2M (31.1% margin), reflecting lower revenue, reduced gross margin (65.4% vs. 71.6%), and higher operating expenses.
-
Full-Year Guidance Slashed
Management now expects 2026 revenue above $175M and Adjusted EBITDA above $25M, a significant reduction from prior expectations, with procedure revenue still negative year-over-year in H2.
Analysis · BTMD · Life Sciences
A sharp reversal from profit to loss in Q2 2026 underscores deepening strain at Biote. Revenue fell 9.5% and Adjusted EBITDA collapsed to $5.6M from $15.2M a year ago, as the voluntary pellet recall continued to weigh on procedure revenue and margins. Management responded by slashing full-year guidance, now calling for revenue above $175M and Adjusted EBITDA above $25M—a significant downgrade from the trajectory implied by prior commentary. With cash down to $11.2M from $24.1M at year-end and a recent CEO departure, the results highlight mounting operational and financial pressure.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.3% of the 1065 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BTMD was trading at $1.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.9M. The 52-week trading range was $1.27 to $4.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.